Placebo matching with Dapagliflozin

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Type 2 Diabetes

Phase 3

Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes

CompletedNCT01606007

AstraZenecaType 2 Diabetes

Start: 2012-07-31End: 2014-01-31Updated: 2017-05-15

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

CompletedNCT01646320

AstraZenecaType 2 Diabetes

Start: 2012-09-30End: 2015-02-28Updated: 2016-06-22

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

CompletedNCT02284893

AstraZenecaType 2 Diabetes

Start: 2014-09-09End: 2016-09-20Updated: 2018-06-01

Related Papers

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes Obesity and Metabolism2019-07-3110 citations

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.

2018-08-0112 citations

Durability of Glycemic Control with Dapagliflozin vs. Saxagliptin in Patients with Inadequately Controlled Type 2 Diabetes

Diabetes2018-06-22

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.

2018-05-255 citations

Dreifachtherapie mit Dapagliflozin (DAPA) als Add-on zu Saxagliptin (SAXA) plus Metformin (MET): Analyse der offenen SAXA+MET-Vorlaufzeit einer Phase-3-Studie

Diabetologie und Stoffwechsel2016-04-19

Combined Saxagliptin and Dapagliflozin Reduce Blood Glucose Levels in T2DM Patients

MD Conference Express2014-11-01